undamentalytics Newsletter
Sign in

Inmune Bio, Inc. income statement

In fiscal 2025, Inmune Bio, Inc. reported revenue of $50,000, up 257.1% on the year before, operating income of −$47.4m (a -94766.0% margin) and net income of −$45.9m, or −$1.86 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue00000000
Research and development0362117203321
General and administrative1969910910
Operating income−1−12−12−29−26−30−43−47
Interest expense———12200
Income before tax—————304246
Income tax00——————
Net income−1−12−12−30−27−30−42−46
Diluted EPS−$0.13−$1.43−$1.01−$1.88−$1.52−$1.67−$2.11−$1.86
Diluted shares (average)7m9m12m16m18m18m20m25m
EBITDA———————−47

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: INMB vs LYELAIM vs INMBIBIO vs INMB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inmune Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inmune Bio, Inc.